MannKind (MNKD) Tops Q4 EPS by 73c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results
March 16, 2017 4:01 PM EDTConference Call to Begin Today at 5:00 PM ET
VALENCIA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) (TASE: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2016. Key results include:
Total revenue for the quarter of $12.4 million, including $10.2 million from insulin sales to Sanofi, and net income for the fourth quarter of $54.0 million including $72.0 million from the extinguishment of debt owed to SanofiTotal revenue for 2016 of $174.8 million, including $172.0 million in... More